Novartis tests One-Shot cell therapy to halt progressive MS

NCT ID NCT06675864

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This early-phase study is testing whether a single dose of an experimental cell therapy called YTB323 is safe for people with progressive multiple sclerosis (MS) who haven't had recent relapses. The trial will enroll 28 participants who will receive the treatment and then be monitored for 2 years, with additional long-term follow-up planned for 13 more years. Researchers will track safety, measure how the therapy affects disability progression, and study how the treatment behaves in the body.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Darlinghurst, New South Wales, 2010, Australia
Novartis Investigative Site
RECRUITING

Melbourne, Victoria, 3004, Australia
Novartis Investigative Site
RECRUITING

Québec, Quebec, G1J 1Z4, Canada
Novartis Investigative Site
RECRUITING

Bron, 69677, France
Novartis Investigative Site
RECRUITING

Montpellier, 34090, France
Novartis Investigative Site
RECRUITING

Nancy, 54035, France
Novartis Investigative Site
RECRUITING

Rennes, 35033, France
Novartis Investigative Site
RECRUITING

Essen, 45147, Germany
Novartis Investigative Site
RECRUITING

Ulm, 89081, Germany
Novartis Investigative Site
RECRUITING

Genova, GE, 16132, Italy
Novartis Investigative Site
RECRUITING

Milan, MI, 20132, Italy
Novartis Investigative Site
RECRUITING

Barcelona, Catalonia, 08035, Spain
Novartis Investigative Site
RECRUITING

Majadahonda, Madrid, 28222, Spain
Novartis Investigative Site
RECRUITING

Málaga, 29010, Spain
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Bern, 3010, Switzerland
Novartis Investigative Site
RECRUITING

Lausanne, 1011, Switzerland
Novartis Investigative Site
RECRUITING

Zurich, 8091, Switzerland

Conditions

Explore the condition pages connected to this study.

PROGRESSIVE MULTIPLE SCLEROSIS